Table 1.
Characteristics of IDH-mutant patients with serum 2-HG measurements.
| Patient | Primary lesion |
Serum 2-HG (ng/mL) | Tumor volume (cm3) | IDH mutation | Tumor grade |
Time to metastasis (months) |
Clinical outcome |
|---|---|---|---|---|---|---|---|
| CS07 | Femur | 520.96 | 1,650 | IDH1 R132S | 3 | At diagnosis | DOD |
| CS11 | Femur | 426.24 | 150 | IDH2 R172M | Dediff | At diagnosis | DOD |
| CS12 | Humerus | 411.44 | 900 | IDH2 R172S | Dediff | 25 | DOD |
| CS33 | Pelvis | 378.88 | 399 | IDH1 R132L | Dediff | At diagnosis | DOD |
| CS01 | Humerus | 364.08 | 29 | IDH1 R132C | 1 | 119 | AWD |
| CS26 | Vertebrae | 364.08 | 310 | IDH1 R132L | 2 | DOD | |
| CS04 | Humerus | 353.72 | 11 | IDH2 R172M | 2 | NED | |
| CS32 | Fibula | 344.84 | 16 | IDH1 R132C | 2 | NED | |
| CS37 | Metatarsal | 333.00 | 34 | IDH1 R132C | 2 | NED | |
| CS05 | Femur | 312.28 | 88 | IDH1 R132G | 2 | NED | |
| CS10 | Femur | 259.00 | 60 | IDH2 R172S | Dediff | 2 | DOD |
Dediff: dedifferentiated.